Brain tumor stem cell-associated antigens (BTSC antigens)

Brain tumor stem cell-associated antigens (BTSCAAs) represent a heterogeneous group of molecular markers expressed by brain tumor stem cells (BTSCs), which are a subpopulation of cells within gliomas (particularly glioblastoma) and other brain tumors that possess self-renewal and multi-lineage differentiation potential (Lathia et al., 2015, Nature Reviews Cancer). These antigens, which include cell surface proteins like CD133 and IL13Rα2 as well as intracellular proteins like SOX2 and Nestin, are critical for maintaining the "stemness" of the tumor, driving therapeutic resistance, and facilitating tumor recurrence after standard-of-care treatments (Bao et al., 2006, Nature). Because BTSCs are often resistant to radiotherapy and chemotherapy, these antigens have become primary targets for novel immunotherapies, including dendritic cell vaccines and chimeric antigen receptor (CAR) T-cell therapies (Vescovi et al., 2006, Nature Reviews Cancer). For example, the vaccine ICT-107 was designed to target six specific BTSC-associated antigens—MAGE-A1, AIM-2, HER2, gp100, IL13Rα2, and TRP-2—to induce a comprehensive immune response against the tumor-initiating population (Wen et al., 2019, Neuro-Oncology). However, the clinical utility of targeting these antigens is often complicated by high intratumoral heterogeneity and the risk of antigen escape, where the tumor evolves to lose expression of the targeted marker (Brown et al., 2016, NEJM).

Other names

Glioblastoma stem cell markersGSC antigensBrain tumor-initiating cell (BTIC) antigensBTSC markers

Induction of antigen-specific cytotoxic T-cell responses or direct antibody-mediated/CAR-T mediated lysis of stem-like tumor cells.